NanoLogix Technology Being Configured For Rapid Ebola Virus Detection
2014年10月14日 - 10:30PM
ビジネスワイヤ(英語)
Seeks Corporate Project Partner For Ebola
Detection Kits
NanoLogix Inc. (NNLX), an innovative biotechnology company in
Northeastern Ohio announces that it is configuring its N-Assay
Rapid diagnostic kits for both Ebola Virus and Enterovirus
detection and identification. NanoLogix CEO Bret Barnhizer stated,
“The Company has been aware of the virus detection capabilities of
the technology since the N-Assay development. Viruses viewed as
public health concerns prior to Ebola and Enterovirus were
Influenza, the common cold, and HIV, none of which have an
immediate or near-immediate threat of mortality. Until recently,
NanoLogix has been focused solely on the use of their N-Assay kit
for bacteria detection and identification. Now, with the recent
outbreaks of both Ebola and Enterovirus there is an immediate need
for configuration of the N-Assay for viruses. NanoLogix facilities
are not designed for work on viruses, for this specific project we
are seeking a corporate partner with the facilities necessary to
bring the new N-Assay (V) to the market as quickly as possible. We
consider this a matter of national security and an emergency
priority. We are in discussions with potential partners, positioned
with strong ties to the US government, who understand the serious
threat these viruses represent.”
The NanoLogix N-Assay (V) ELISA is one of six technologies that
may be used for virus detection and identification, the N-Assay (V)
has unique qualities that contribute to both its rapid detection
capability and long term durability that should be attractive to
personnel in both developed and remote locations interested in a
screening test that may provide results for Ebola or other viral
threats in 30 minutes to a few hours.
Supporting information on the N-Assay (B), used for bacterial
detection and identification and evidence of the capabilities of
one version of the technology can be found by following this
link:
http://nanologix.com/resources/index.html
Sebastian Faro, MD, PhD, is considered one of the top experts in
the world on Infectious diseases of women's reproductive systems.
Dr. Faro made the following comments: "N-Assay ELISA technology has
been applied to the rapid identification of specific bacteria, e.g.
Streptococcus agalactiae (GBS), Neisseria gonorrhoeae, &
Enterococcus faecalis. This technology has been used to rapidly
identify strains that are resistant to specific antibiotics. This
technology significantly reduces the time from specimen submission
to identifying these bacteria and resistance to specific
antibiotics. This N-Assay ELISA technology can be applied to
identifying viruses and is inexpensive. This technology does not
require expensive equipment which makes this technology ideal for a
variety of laboratory environments.”
His presentation on the N-Assay is in the following YouTube
links:
https://www.youtube.com/watch?v=TCG_ihwwrBQ
https://www.youtube.com/watch?v=kshzguaO7uk
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical, National
Defense, and homeland security applications, NanoLogix technology
is applicable in pharmaceutical, industrial, veterinary and
environmental testing.
Patents granted to NanoLogix can be used in the areas of applied
microbiology, soil microbiology and bioremediation, microbial
physiology, molecular biology, pharmacology, pharmaco-kinetics, and
antibiotic sensitivity.
For more information visit: http://www.nanologix.com
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
NanoLogix, Inc.Carol Surrena, 330-534-0800info@nanologix.com
NanoLogix (CE) (USOTC:NNLX)
過去 株価チャート
から 11 2024 まで 12 2024
NanoLogix (CE) (USOTC:NNLX)
過去 株価チャート
から 12 2023 まで 12 2024